Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Nicholas Florko, Communications Officer, Global Trade Watch
w. (202) 454-5108

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


July 21, 2010  

FDA’s Partial Hold on Unethical Diabetes Drug Trial Does Not Do Enough to Protect Patients

Statement of Dr. Sidney Wolfe, Director, Public Citizen’s Health Research Group

The Food and Drug Administration (FDA) has gone only half-way in stopping the unethical TIDE study by halting the recruitment of any new patients. To allow the experiment to continue at all is a major breach in the FDA’s obligation to protect people in clinical trials. In May of this year, we wrote to the FDA urging a complete cessation of the TIDE trial. In late 2008, we petitioned the FDA to ban the diabetes drug rosiglitazone, better known as Avandia.

By stating that “Patients already enrolled in the trial will be allowed to continue to participate,” the FDA is failing to protect the more than 1,100 people already enrolled in the trial from the needless damage that will occur to those randomized to get rosiglitazone instead of pioglitazone, commonly known as Actos.

As the Institute of Medicine told the FDA last week, when new information concerning a drug becomes available, the participants need to be informed. How many of these 1,100 people would drop out of the study if they were told, for example, that an FDA advisory committee voted 21 to 3 (with 9 unsure) that the heart risks of rosiglitazone are greater than those of pioglitazone? This compounds the previous lack of informed consent about the two key facts – that an expert committee of the American Diabetes Association unanimously concluded that Avandia should not be used for treating diabetes and that there has been more than an 80 percent decrease in prescriptions for the drug.

By failing to completely stop the TIDE trial and to ban the drug, the FDA is not only guaranteeing that the 1,100 patients in the TIDE trial continue to be subjected to an unacceptably dangerous drug, but also hundreds of thousands of people will continue to use the drug in this country.

 To read Public Citizen’s letter to the FDA, sent in May, to stop the TIDE trial, visit: http://www.citizen.org/Page.aspx?pid=3312.


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.